These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 12633015

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Thiazolidinediones.
    Yki-Järvinen H.
    N Engl J Med; 2004 Sep 09; 351(11):1106-18. PubMed ID: 15356308
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Insulin resistance in patients with polycystic ovary syndrome.
    Schröder AK, Tauchert S, Ortmann O, Diedrich K, Weiss JM.
    Ann Med; 2004 Sep 09; 36(6):426-39. PubMed ID: 15513294
    [Abstract] [Full Text] [Related]

  • 5. [Against insulin resistance. Insulin sensitizers].
    Verspohl EJ, Weiland F.
    Pharm Unserer Zeit; 2002 Sep 09; 31(3):280-92. PubMed ID: 12071125
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cardiometabolic features of polycystic ovary syndrome.
    Hoffman LK, Ehrmann DA.
    Nat Clin Pract Endocrinol Metab; 2008 Apr 09; 4(4):215-22. PubMed ID: 18250636
    [Abstract] [Full Text] [Related]

  • 8. [Polycystic ovarian syndrome is a health risk].
    Hippeläinen M.
    Duodecim; 2002 Apr 09; 118(10):981-3. PubMed ID: 12238006
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers.
    Sharma ST, Nestler JE.
    Best Pract Res Clin Endocrinol Metab; 2006 Jun 09; 20(2):245-60. PubMed ID: 16772155
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The link between polycystic ovarian syndrome and type 2 diabetes: preventive and therapeutic approach in Israel.
    Jakubowicz D, Wainstein J, Homburg R.
    Isr Med Assoc J; 2012 Jul 09; 14(7):442-7. PubMed ID: 22953622
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [The role of peroxisome proliferator-activated receptor gamma in the pathogenesis of diabetes and atheromatosis].
    Gacka M, Adamiec R, Dobosz T, Szymaniec S, Bednarska-Chabowska D.
    Przegl Lek; 2004 Jul 09; 61(12):1436-9. PubMed ID: 15850344
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Insulin-sensitising agents in polycystic-ovary syndrome.
    Sattar N, Hopkinson ZE, Greer IA.
    Lancet; 1998 Jan 31; 351(9099):305-7. PubMed ID: 9652605
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A new shine on an old med. The story of metformin's past, present, and possible future.
    Gebel E.
    Diabetes Forecast; 2010 Dec 31; 63(12):48-51. PubMed ID: 21192531
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.